US Stem Cell Inc (USRM)

[STOXMONSTER]

Financial highlights from 2016 include:

Revenue up by 38% from $2.2M in 2015 to $3.03M in 2016
Current liabilities down by $1.9M, or 23.8%, from $8.0M in 2015 to $6.1M in 2016
Operating Expenses down 16.5% (or $631,825) from 3.82M in 2015 to $3.19M in 2016
Net loss improved 136% from $2.6M (gain) in 2015 to $1.15M in 2016
And for the first time in the company’s history, U.S Stem Cell, Inc. ended the year on a cash positive note: $108,596 cash positive as a result of operations in 2016 compared to $844,690 cash negative from operations in 2015.